Edwards Lifesciences

JC Medical specializes in the design and development of transcatheter valve replacement products aimed at treating structural heart diseases. These products are intended for minimally invasive procedures, providing a solution for patients suffering from heart failure symptoms such as shortness of breath, fatigue, and chest pain. The company's innovative system includes a proprietary anchor mechanism that specifically addresses the needs of patients with aortic regurgitation. By offering a more affordable treatment option, JC Medical enables healthcare providers to effectively manage this condition, ultimately enhancing patient outcomes and accessibility to vital heart disease treatments.

Genesis Medtech is a medical device company that develops a variety of products aimed at the value segment of the healthcare market. The company specializes in interventional devices for cardiology, oncology, peripheral vascular, and neurovascular applications. Its product range includes both surgical and interventional devices designed for enhanced placement accuracy and adaptability to diverse anatomical requirements. Additionally, Genesis Medtech offers ultrasonic energy devices and endoscopic linear cutting staplers. The company is committed to making quality healthcare affordable and accessible, particularly in emerging markets across the Asia Pacific region and beyond.

JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

Affluent Medical is a medical device company based in Paris, France, specializing in the design, development, manufacturing, and marketing of implantable prostheses. Founded in 2011, the company focuses on next-generation minimally invasive devices aimed at treating severe medical conditions. Its product lineup includes the Kardiozis prosthesis, which addresses abdominal aortic aneurysms, and the Kalios and Epygon implants, designed for mitral valve repair and replacement. Kalios addresses post-operative leakage and recurrent mitral insufficiency without the need for additional surgeries, while Epygon is notable for being a developing transcatheter valve that restores natural blood flow. Additionally, Affluent Medical has created Artus, the first electronically activatable artificial sphincter for the treatment of severe urinary incontinence in both men and women.

Caption Health, Inc. is a technology company that specializes in artificial intelligence-driven software solutions for ultrasound examinations. Founded in 2013 and headquartered in Brisbane, California, the company offers Caption AI, a system designed to assist healthcare providers in acquiring and interpreting ultrasound images. This software provides real-time guidance during exams, automates quality assessments, and facilitates the interpretation of ultrasound results, enabling practitioners to capture high-quality diagnostic images more efficiently. As the adoption of the Caption AI platform grows, Caption Health plans to enhance its technology and expand its clinical capabilities, aiming to integrate its solutions into a wider range of healthcare settings.

Corvia Medical is a medical device company based in Andover, Massachusetts, established in 2009. The company specializes in developing innovative solutions for heart failure, particularly through its InterAtrial Shunt Device (IASD). This transcatheter device is designed to address diastolic heart failure, also known as heart failure with preserved ejection fraction. The IASD works by creating a small opening between the left and right atria, which helps to lower blood pressure in the left atrium and lungs. This reduction in pressure aims to alleviate symptoms and slow the progression of heart failure, allowing patients to maintain a healthier lifestyle and reduce their risk of severe heart-related complications.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

CAS Medical Systems is dedicated to the design and manufacture of innovative, non-invasive technologies and products vital to patient care in the most challenging clinical environments. With a reputation for the highest quality products available in the markets it serves, CASMED products are used by clinicians worldwide.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Harpoon Medical, Inc. is a medical device company based in Baltimore, Maryland, focused on developing and commercializing innovative transcatheter devices for patients with mitral valve disease. Founded in 2013, the company specializes in a minimally invasive, image-guided surgical tool designed for beating heart mitral valve repair. This technology allows surgeons to access and repair the mitral valve through a small incision between the ribs, eliminating the need for cardiac arrest or cardiopulmonary bypass. The Harpoon device inserts "bulky knot" neochords into the valve leaflets, effectively addressing mitral valve regurgitation. The introduction of this device is expected to significantly shorten the duration of traditional open-heart surgeries from several hours to approximately 60 minutes, while also reducing recovery time from weeks to just days. As of December 2017, Harpoon Medical operates as a subsidiary of Edwards Lifesciences Corporation.

Valtech Cardio Ltd. is a medical device company based in Or Yehuda, Israel, specializing in the development and manufacturing of cardiovascular devices aimed at treating mitral regurgitation and facilitating tricuspid valve repair and replacement. The company focuses on minimally invasive transcatheter heart valve technologies, allowing patients to avoid open-heart surgery. Its key products include the Cardioband System, which performs mitral valve reconstruction via transfemoral direct annuloplasty, and the Cardiovalve system, a transfemoral transseptal replacement option for the mitral valve. Additionally, Valtech offers the Cardinal adjustable annuloplasty ring, which allows surgeons to optimize the ring size during surgery. The company's pipeline includes innovative products such as Cardioband Tricuspid, designed for mitral regurgitation, and V-Chordal, an adjustable implanted chord for repairing valve prolapse. Founded in 2006, Valtech Cardio operates as a subsidiary of Zeppelin Zox Ltd. since January 2017.

Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.

CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.

Middle Peak Medical is a privately held medical device company dedicated to developing innovative solutions for mitral valve disease. The company focuses on creating a proprietary device designed to address unmet needs in treating mitral valve regurgitation. This novel technology aims to restore mitral valve competence in both functional and degenerative conditions by providing a new posterior surface for the anterior leaflet to seal properly. The device is applicable in both percutaneous catheter-based interventions and minimally invasive or open-heart cardiac surgeries, positioning Middle Peak Medical as a key player in advancing treatment options for patients with mitral valve disorders.

BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, specializing in the development of a system designed to improve embolic cerebral protection. This innovative system aims to assist interventionalists in minimizing the occurrence of embolic strokes during cardiovascular procedures. By focusing on enhancing patient safety, Embrella Cardiovascular addresses a critical need in the healthcare sector, particularly in the realm of cardiovascular interventions.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, specializing in the development of a system designed to improve embolic cerebral protection. This innovative system aims to assist interventionalists in minimizing the occurrence of embolic strokes during cardiovascular procedures. By focusing on enhancing patient safety, Embrella Cardiovascular addresses a critical need in the healthcare sector, particularly in the realm of cardiovascular interventions.

Myocor is a medical company based in Minnesota that specializes in developing and distributing therapeutic devices aimed at treating mitral valve insufficiency and congestive heart failure. Founded in 1996, Myocor focuses on innovations that enhance cardiac function and improve clinical outcomes for patients with late-stage heart failure. One of its key products, Coapsys, employs a system of pads and a tensioned string inserted through the heart to reshape an enlarged heart and optimize the performance of a leaky mitral valve. Through its technologies, Myocor aims to address the challenges associated with heart failure and provide effective treatment options for affected individuals.

Whitland Research focused on the development of critical care monitoring technologies.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.